

## **Gemeinsame Pressemitteilung vom 12. April 2016**

Seite 1/2

### **Pharma Dialog – The work starts now**

Berlin. Today, the German government submitted its report on the Pharma Dialog. The agencies involved were the Ministry of Health, the Ministry for Education and Research, and the Ministry for Economic Affairs and Energy.

What was rated positively by the participating pharmaceutical and biotechnology associations was that the German government has jointly discussed course-setting measures for Germany as a health care location with the pharmaceutical industry, the scientific arena and the IG BCE labor union. The Head Association of Statutory Health Insurance Funds and the Federal Joint Committee also joined the discussions for some items of key importance to them. During these talks, the participants of the Pharma Dialog were not interested in lodging demands but rather in jointly developing solutions.

The associations welcome the fact that the German government expressly recognizes the significance of the pharmaceutical and the biotechnology industry for pharmaceutical care, patients' quality of life and Germany as a location for business. This mutual appreciation is important for an industry that shares responsibility in the health and social security system.

The report of the German government is the first result of the Pharma Dialog and names activity areas across departmental lines.

The dialog partners were in agreement regarding the topic of antibiotics and its national and global dimension: Among others, they agreed to support education initiatives and to advance the development of new antibiotics in product development partnerships.

Plans also include the provision of support regarding the development and use of rapid tests for the targeted application of antibiotics.

Controversial subjects still include the adjustment of the early benefit assessment and the reimbursement amount negotiations, a retroactive price setting for innovative pharmaceuticals, an improvement in the general framework for the further development of known active ingredients and the question of how tenders for generic drugs can be more strongly oriented toward a secure pharmaceutical supply.

Therefore, beyond mere appeals, a balanced and sustainable package of measures should now be jointly developed. The prerequisites are in place, because the German government will continue its discussions with the dialog partners. It remains the objective of the Pharma Dialog to strengthen Germany as a location for research, production and business in order to ensure that patients continue to receive high-quality health care in the future.

## Media contacts

### **BAH**

Holger Wannewetsch  
Phone +49 (0)30 3087596-122  
wannewetsch@bah-bonn.de

### **BIO Deutschland**

Dr. Claudia Englbrecht  
Phone +49 (0)30 72625-132  
englbrecht@biodeutschland.org

### **BPI**

Julia Richter  
Phone +49 (0)30 27909-131  
j.richter@bpi.de

### **Pro Generika**

Bork Bretthauer  
Phone +49 (0)30 8161609-10  
bretthauer@progenerika.de

### **vfa**

Dr. Jochen Stemmler  
Phone +49 (0)30 20604-203  
j.stemmler@vfa.de

Seite 2/2

Gemeinsame  
Pressemitteilung  
vom 12. April 2016